Cardiac Surgery Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
Cardiac Surgery Department, Hospital Universitario Quiron-Madrid, Madrid, Spain.
Eur J Cardiothorac Surg. 2022 Aug 3;62(3). doi: 10.1093/ejcts/ezac149.
The goal of this study was to analyse early- and long-term outcomes of aortic valve reimplantation (David operation) in patients with heritable thoracic aortic disease.
This is a retrospective observational analysis using data from a prospectively maintained surgical database from March 2004 to April 2021. Patients with heritable thoracic aortic disease were included in the study.
A total of 157 patients with aortic root aneurysm with the diagnosis of heritable thoracic aortic disease received the David procedure. Marfan syndrome was found in 143 (91.1%) patients, Loeys-Dietz in 13 and Ehler-Danlos in 1 patient. The median age was 35.0 (IQR: 17.5) years and the median ascending aorta diameter in the Valsalva sinuses was 48 mm (IQR: 4). A Valsalva graft was used in 8 patients; the David V technique was performed in the rest of the cases. The median follow-up time was 7.3 years [standard deviation: 0.58, 95% confidence interval (CI): 6.12-8.05]. Only 2 patients died during the follow-up period. The overall survival was 99% (95% CI: 95%; 99%); 98% (95% CI: 92%; 99%); and 98% (95% CI: 92%; 99%) at 5, 10 and 15 years. Freedom from significant aortic regurgitation (AR> II), reintervention and postoperative type-B dissection was 90% (95% CI: 77%; 95%), 96% (95% CI: 91%; 99%) and 87% (95% CI: 68%; 95%) at 15 years, respectively. No differences were found in any outcome between Marfan syndrome and Loeys-Dietz syndrome. No statistically significant differences in survival were found when we compared expected gender- and age-specific population survival values.
The David operation is an excellent option for the treatment of patients with heritable thoracic aortic disease and dilatated aortic root. Surgical expertise in referral centres is essential to achieve the best long-term results.
本研究旨在分析遗传性胸主动脉疾病患者行主动脉瓣再植(David 手术)的早期和长期结果。
这是一项回顾性观察性分析,使用 2004 年 3 月至 2021 年 4 月期间前瞻性维护的外科数据库中的数据。本研究纳入了遗传性胸主动脉疾病患者。
共 157 例主动脉根部瘤患者诊断为遗传性胸主动脉疾病,接受了 David 手术。马凡综合征患者 143 例(91.1%),Loeys-Dietz 综合征 13 例,Ehler-Danlos 综合征 1 例。中位年龄为 35.0(IQR:17.5)岁,升主动脉窦部直径 48mm(IQR:4)。8 例患者使用了 Valsalva 移植物,其余患者均采用 David V 技术。中位随访时间为 7.3 年[标准差:0.58,95%置信区间(CI):6.12-8.05]。随访期间仅 2 例患者死亡。总体生存率为 99%(95%CI:95%;99%);5 年、10 年和 15 年时分别为 98%(95%CI:92%;99%)和 98%(95%CI:92%;99%)。无明显主动脉瓣反流(AR>II)、再次干预和术后 B 型夹层的无事件生存率分别为 90%(95%CI:77%;95%)、96%(95%CI:91%;99%)和 87%(95%CI:68%;95%)。马凡综合征和 Loeys-Dietz 综合征在任何结果方面均无差异。与预期的性别和年龄特定人群生存率值相比,生存率无统计学差异。
David 手术是治疗遗传性胸主动脉疾病和主动脉根部扩张患者的一种极好选择。转诊中心的外科专业知识对于实现最佳长期结果至关重要。